Results 61 to 70 of about 16,733 (229)

In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula

International Journal of Infectious Diseases, 2020
Objectives: Our aim was to assess the susceptibility of carbapenem-resistant Enterobacterales (CRE) from the Arabian Peninsula to a broad spectrum of antibiotics, including fosfomycin, ceftazidime-avibactam, and aztreonam-avibactam.
Ágnes Sonnevend, Akela Ghazawi, Dania Darwish, Greeshma Barathan, Rayhan Hashmey, Tanveer Ashraf, Tahir A. Rizvi, Tibor Pál   +7 more
doaj   +1 more source

In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales [PDF]

Frontiers in Cellular and Infection Microbiology, 2021
ObjectivesTo assess the efficacy of aztreonam-avibactam-auranofin (ATM-AVI-AUR) against a collection of 88 carbapenemase-producing Enterobacterales (CPE) clinical isolates and 6 in vitro selected ATM-AVI-resistant CPE with CMY-16 Tyr150Ser and Asn346His mutants or transformants.MethodsMICs of imipenem, ceftazidime-avibact8am (CAZ-AVI), ATM-AVI, CAZ-AVI-
Wen Wang, Wen Wang, Shifeng Huang, Chunhong Zou, Chunhong Zou, Yanhui Ding, Huijuan Wang, Shuli Pu, Yunfeng Liao, Hong Du, Deqiang Wang, Deqiang Wang, Liang Chen, Liang Chen, Siqiang Niu   +14 more
openaire   +3 more sources

Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiella pneumoniae infections

iScience, 2023
Summary: Developing an effective therapy to overcome carbapenemase-positive Klebsiella pneumoniae (CPKp) is an important therapeutic challenge that must be addressed urgently.
Dhammika Leshan Wannigama, Aye Mya Sithu Shein, Cameron Hurst, Peter N. Monk, Parichart Hongsing, Phatthranit Phattharapornjaroen, William Graham Fox Ditcham, Puey Ounjai, Thammakorn Saethang, Naphat Chantaravisoot, Pattama Wapeesittipan, Sirirat Luk-in, Sasipen Sae-Joo, Sumanee Nilgate, Ubolrat Rirerm, Chanikan Tanasatitchai, Naris Kueakulpattana, Matchima Laowansiri, Tingting Liao, Rosalyn Kupwiwat, Rojrit Rojanathanes, Natharin Ngamwongsatit, Somkanya Tungsanga, Asada Leelahavanichkul, Naveen Kumar Devanga Ragupathi, Vishnu Nayak Badavath, S.M. Ali Hosseini Rad, Talerngsak Kanjanabuch, Nattiya Hirankarn, Robin James Storer, Longzhu Cui, Mohan Amarasiri, Hitoshi Ishikawa, Paul G. Higgins, Stephen M. Stick, Anthony Kicic, Tanittha Chatsuwan, Shuichi Abe   +37 more
doaj   +1 more source

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam [PDF]

, 2022
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system ...
Avison, Matthew B, Dulyayangkul, Punyawee, Satapoomin, Aim   +2 more
core   +2 more sources

Emerging treatment options for multi-drug-resistant bacterial infections [PDF]

, 2021
Antimicrobial resistance (AMR) remains one of the top public health issues of global concern. Among the most important strategies for AMR control there is the correct and appropriate use of antibiotics, including those available for the treatment of AMR ...
Andini R., Durante-Mangoni E., Giurazza R., Mazza M. C., Pace M. C., Sansone P.   +5 more
core   +1 more source

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)

Open Forum Infectious Diseases, 2023
Background As the frequency of metallo-β-lactamase (MBL)-producing Enterobacterales is increasing worldwide, effective antimicrobials to treat the infections caused by these organisms are urgently needed.
H. Sader, R. Mendes, C. Carvalhaes, J. Kimbrough, M. Castanheira   +4 more
semanticscholar   +1 more source

In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019

Journal of Global Antimicrobial Resistance, 2022
Infections caused by drug-resistant Enterobacterales including those producing metallo-β-lactamases (MBLs) are particularly challenging due to limited therapeutic options. The drug combination aztreonam/avibactam (ATM-AVI) is under clinical development for treating serious infections caused by these strains. This study assessed the in vitro activity of
Gian Maria Rossolini, Gregory Stone, Michal Kantecki, Francis F. Arhin   +3 more
openaire   +4 more sources

Activity of nacubactam (RG6080/OP0595) combinations against metallo-β-lactamase (MBL)-producing Enterobacteriaceae [PDF]

, 2018
Background: Diazabicyclooctanes (DBOs) are promising β-lactamase inhibitors. Some, including nacubactam (OP0595/RG6080), also bind PBP2 and have an enhancer effect, allowing activity against Enterobacteriaceae with MBLs, which DBOs do not inhibit.
Haldimann, Andreas, Livermore, David, Mushtaq, Shazad, Vickers, Anna, Woodford, Neil   +4 more
core   +1 more source

A Study on Ceftazidime/Avibactam and Aztreonam Synergy Among Aztreonam-resistant Metallo-β-lactamase Producing Enterobacterales in a Tertiary Care Hospital

Mediterranean Journal of Infection, Microbes and Antimicrobials
Introduction: Global detection of bacteria harboring metallo-β-lactamase (MBL) genes has increased at an alarming rate. However, there is no concurrent increase in available antibiotics for treatment, which has turned these infections into a public ...
Adelyn D’SOUZA, Rachana SHETTY, Asha Pai KB   +2 more
doaj   +1 more source

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates

Journal of Antimicrobial Chemotherapy, 2023
Background Aztreonam/avibactam is one of the last therapeutic options for treating infections caused by NDM-like-producing Enterobacterales. However, PBP3-modified and NDM-producing Escherichia coli strains that co-produce CMY-42 have been shown to be ...
C. Terrier, P. Nordmann, Mustafa Sadek, L. Poirel   +3 more
semanticscholar   +1 more source